|
1
|
Lai CL, Ratziu V, Yuen MF and Poynard T:
Viral hepatitis B. Lancet. 362:2089–2094. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guidotti LG and Chisari FV: Immunobiology
and pathogenesis of viral hepatitis. Annu Rev Pathol. 1:23–61.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rehermann B, Fowler P, Sidney J, et al:
The cytotoxic T lymphocyte response to multiple hepatitis B virus
polymerase epitopes during and after acute viral hepatitis. J Exp
Med. 181:1047–1058. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bertoletti A and Naoumov NV: Translation
of immunological knowledge into better treatments of chronic
hepatitis B. J Hepatol. 39:115–124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bertoletti A, D’Elios MM, Boni C, et al:
Different cytokine profiles of intraphepatic T cells in chronic
hepatitis B and hepatitis C virus infections. Gastroenterology.
112:193–199. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Z, Zhang JY, Wang LF and Wang FS:
Immunopathogenesis and prognostic immune markers of chronic
hepatitis B virus infection. J Gastroenterol Hepatol. 27:223–230.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sakaguchi S, Yamaguchi T, Nomura T and Ono
M: Regulatory T cells and immune tolerance. Cell. 133:775–787.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyara M and Sakaguchi S: Natural
regulatory T cells: mechanisms of suppression. Trends Mol Med.
13:108–116. 2007. View Article : Google Scholar
|
|
9
|
Xu D, Fu J, Jin L, et al: Circulating and
liver resident CD4+CD25+ regulatory T cells actively influence the
antiviral immune response and disease progression in patients with
hepatitis B. J Immunol. 177:739–747. 2006.
|
|
10
|
Stoop JN, van der Molen RG, Baan CC, et
al: Regulatory T cells contribute to the impaired immune response
in patients with chronic hepatitis B virus infection. Hepatology.
41:771–778. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Franzese O, Kennedy PT, Gehring AJ, et al:
Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T
cells in patients with hepatitis B virus infection. J Virol.
79:3322–3328. 2005.
|
|
12
|
Feng IC, Koay LB, Sheu MJ, et al:
HBcAg-specific CD4+CD25+ regulatory T cells modulate immune
tolerance and acute exacerbation on the natural history of chronic
hepatitis B virus infection. J Biomed Sci. 14:43–57. 2007.
|
|
13
|
Taams LS, Vukmanovic-Stejic M, Smith J, et
al: Antigen-specific T cell suppression by human CD4+CD25+
regulatory T cells. Eur J Immunol. 32:1621–1630. 2002.
|
|
14
|
Liaw YF and Chu CM: Hepatitis B virus
infection. Lancet. 373:582–592. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dienstag JL: Hepatitis B virus infection.
N Engl J Med. 359:1486–1500. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sprengers D, Stoop JN, Binda RS, et al:
Induction of regulatory T-cells and interleukin-10-producing cells
in non-responders to pegylated interferon-alpha therapy for chronic
hepatitis B. Antivir Ther. 12:1087–1096. 2007.PubMed/NCBI
|
|
17
|
Rico MA, Quiroga JA, Subirá D, et al:
Hepatitis B virus-specific T-cell proliferation and cytokine
secretion in chronic hepatitis B e antibody-positive patients
treated with ribavirin and interferon alpha. Hepatology.
33:295–300. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maini MK, Reignat S, Boni C, et al: T cell
receptor usage of virus-specific CD8 cells and recognition of viral
mutations during acute and persistent hepatitis B virus infection.
Eur J Immunol. 30:3067–3078. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boni C, Penna A, Bertoletti A, et al:
Transient restoration of anti-viral T cell responses induced by
lamivudine therapy in chronic hepatitis B. J Hepatol. 39:595–605.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsai SL, Sheen IS, Chien RN, et al:
Activation of Th1 immunity is a common immune mechanism for the
successful treatment of hepatitis B and C: tetramer assay and
therapeutic implications. J Biomed Sci. 10:120–135. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stoop JN, van der Molen RG, Kuipers EJ,
Kusters JG and Janssen HL: Inhibition of viral replication reduces
regulatory T cells and enhances the antiviral immune response in
chronic hepatitis B. Virology. 361:141–148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Li X, Ye B, et al: Effect of
telbivudine therapy on the cellular immune response in chronic
hepatitis B. Antiviral Res. 91:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koay LB, Feng IC, Sheu MJ, et al:
Hepatitis B virus (HBV) core antigen-specific regulatory T cells
confer sustained remission to anti-HBV therapy in chronic hepatitis
B with acute exacerbation. Hum Immunol. 72:687–698. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nash K: Telbivudine in the treatment of
chronic hepatitis B. Adv Ther. 26:155–169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lai CL, Gane E, Liaw YF, et al:
Telbivudine versus lamivudine in patients with chronic hepatitis B.
N Engl J Med. 357:2576–2588. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lai CL, Leung N, Teo EK, et al: A 1-year
trial of telbivudine, lamivudine, and the combination in patients
with hepatitis B e antigen-positive chronic hepatitis B.
Gastroenterology. 129:528–536. 2005.PubMed/NCBI
|
|
27
|
Lai CL, Gane E, Hsu CW, et al: Two-year
results from the GLOBE trial in patients with hepatitis B: greater
clinical and antiviral efficacy for telbivudine (LdT) vs.
lamivudine Hepatology. 44(Suppl 1): 222A2006.
|
|
28
|
Liaw YF, Gane E, Leung N, et al: 2-Year
GLOBE trial results: telbivudine Is superior to lamivudine in
patients with chronic hepatitis B. Gastroenterology. 136:486–495.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chinese Society of Hepatology, Chinese
Medical Association; Chinese Society for Infectious Diseases,
Chinese Medical Association. Guideline on prevention and treatment
of chronic hepatitis B in China (2005). Chin Med J (Engl).
120:2159–2173. 2007.PubMed/NCBI
|
|
30
|
Shaik GM, Dráberová L and Dráber P,
Boubelík M and Dráber P: Tetraalkylammonium derivatives as
real-time PCR enhancers and stabilizers of the qPCR mixtures
containing SYBR Green I. Nucleic Acids Res. 36:e932008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lan RY, Cheng C, Lian ZX, et al:
Liver-targeted and peripheral blood alterations of regulatory T
cells in primary biliary cirrhosis. Hepatology. 43:729–737. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li S, Gowans EJ, Chougnet C, Plebanski M
and Dittmer U: Natural regulatory T cells and persistent viral
infection. J Virol. 82:21–30. 2008. View Article : Google Scholar
|
|
33
|
Fontenot JD and Rudensky AY: A well
adapted regulatory contrivance: regulatory T cell development and
the forkhead family transcription factor Foxp3. Nat Immunol.
6:331–337. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fontenot JD, Gavin MA and Rudensky AY:
Foxp3 programs the development and function of CD4+CD25+ regulatory
T cells. Nat Immunol. 4:330–336. 2003.
|
|
35
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang G, Liu A, Xie Q, et al: Association
of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and
viral clearance in patients with hepatitis B. Int Immunol.
19:133–140. 2007.
|
|
37
|
Belkaid Y: Regulatory T cells and
infection: a dangerous necessity. Nat Rev Immunol. 7:875–888. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Belkaid Y and Rouse BT: Natural regulatory
T cells in infectious disease. Nat Immunol. 6:353–360. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Alatrakchi N and Koziel M: Regulatory T
cells and viral liver disease. J Viral Hepat. 16:223–229. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rushbrook SM, Hoare M and Alexander GJ:
T-regulatory lymphocytes and chronic viral hepatitis. Expert Opin
Biol Ther. 7:1689–1703. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Billerbeck E, Bottler T and Thimme R:
Regulatory T cells in viral hepatitis. World J Gastroenterol.
13:4858–4864. 2007.PubMed/NCBI
|
|
42
|
Aandahl EM, Michaëlsson J, Moretto WJ,
Hecht FM and Nixon DF: Human CD4+ CD25+ regulatory T cells control
T-cell responses to human immunodeficiency virus and
cytomegalovirus antigens. J Virol. 78:2454–2459. 2004.
|
|
43
|
Cabrera R, Tu Z, Xu Y, et al: An
immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in
hepatitis C virus infection. Hepatology. 40:1062–1071. 2004.
|
|
44
|
Lau GK, Cooksley H, Ribeiro RM, et al:
Impact of early viral kinetics on T-cell reactivity during
antiviral therapy in chronic hepatitis B. Antivir Ther. 12:705–718.
2007.PubMed/NCBI
|
|
45
|
Peng G, Li S, Wu W, Sun Z, Chen Y and Chen
Z: Circulating CD4+ CD25+ regulatory T cells correlate with chronic
hepatitis B infection. Immunology. 123:57–65. 2008.
|
|
46
|
Cao D, Malmström V, Baecher-Allan C,
Hafler D, Klareskog L and Trollmo C: Isolation and functional
characterization of regulatory CD25brightCD4+ T cells from the
target organ of patients with rheumatoid arthritis. Eur J Immunol.
33:215–223. 2003.PubMed/NCBI
|
